Somatostatin imaging of neuroendocrine-differentiated prostate cancer

Thomas A. Hope, Rahul Aggarwal, Jeff P. Simko, Henry F. Vanbrocklin, Charles J. Ryan

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases. Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using 111In-labeled octreotide.

Original languageEnglish (US)
Pages (from-to)540-541
Number of pages2
JournalClinical nuclear medicine
Issue number6
StatePublished - Jun 25 2015

Bibliographical note

Publisher Copyright:
© 2015 Wolters Kluwer Health, Inc. All rights reserved.


  • FDG
  • neuroendocrine
  • octreotide
  • prostate cancer
  • somatostatin


Dive into the research topics of 'Somatostatin imaging of neuroendocrine-differentiated prostate cancer'. Together they form a unique fingerprint.

Cite this